Company intelligence / Profile preview
Chengdu Brilliant Pharmaceutical Co., Ltd.
- Ownership
- Private
- Employees
- ~5000
- Development stage
- Commercial
Overview
Chengdu Brilliant has a robust pipeline with both innovative and generic products. Recent clinical progress includes semaglutide biosimilar in Phase III trials for obesity and BPR‑101 in Phase II trials for bacterial vaginosis. The company has received several product approvals recently and continues to invest heavily in R&D across small molecules and biologics.
- Therapeutic areas
- Men's HealthEndocrinologyPsychiatryCardiovascularInfectious Diseases
- Modalities
- Small moleculesBiomacromolecules (biologics, recombinant proteins, antibody drugs)Cell and gene therapyRadiopharmaceuticalsOligonucleotides
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Chengdu Brilliant Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Brilliant Pharmaceutical Co., Ltd..